Stocks

The most significant catalyst was a report from French publication La Lettre, which claimed that representatives from Eli Lilly had met with France’s Treasury in early December to assess the regulatory framework surrounding a potential acquisition of Abivax. This report reignited speculation about a possible takeover, leading to a sharp increase in the stock price. Although Reuters could not immediately confirm the report, the market reacted strongly to the news. Eli Lilly has been consistently silent on such speculation, reiterating that it does not comment on “business development activity”. Abivax has also remained tight-lipped, not commenting on market rumors or speculation. The market, however, is buzzing with the possibility of a strategic alliance or acquisition between the two companies.

The most significant catalyst was the announcement of a 15-year, $7 billion AI data center lease with Fluidstack. This deal is a testament to Hut 8's strategic pivot from crypto mining to digital infrastructure, positioning the company as a key player in the AI and high-performance computing (HPC) space.

D-Wave Quantum's announcement of its participation in CES 2026 as a sponsor and its plans to showcase its commercial quantum computing technology had a significant impact on the stock price. This event provided an opportunity for the company to demonstrate its award-winning technology and real-world customer success stories, which likely generated excitement and optimism among investors about the company's future prospects.

On December 22, 2025, the company announced that the FDA had approved MYQORZO, a treatment for adults with obstructive hypertrophic cardiomyopathy. This approval likely led to increased investor confidence in the company's potential for growth and profitability.